Target Price | $20.40 |
Price | $3.92 |
Potential |
420.41%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Sonnet BioTherapeutics Holdings Inc 2026 .
The average Sonnet BioTherapeutics Holdings Inc target price is $20.40.
This is
420.41%
register free of charge
$21.00
435.71%
register free of charge
$20.20
415.31%
register free of charge
|
|
A rating was issued by 7 analysts: 6 Analysts recommend Sonnet BioTherapeutics Holdings Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sonnet BioTherapeutics Holdings Inc stock has an average upside potential 2026 of
420.41%
register free of charge
|
Sep '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 0.02 | 1.02 |
86.67% | 5,000.00% | |
EBITDA Margin | -58,850.00% | -4,530.00% |
371.55% | 92.30% | |
Net Margin | -37,200.00% | -1,079.52% |
196.34% | 97.10% |
3 Analysts have issued a sales forecast Sonnet BioTherapeutics Holdings Inc 2025 . The average Sonnet BioTherapeutics Holdings Inc sales estimate is
This results in the following potential growth metrics:
2024 | $20.0k | 86.67% |
---|---|---|
2025 |
$1.0m
5,000.00%
Unlock
|
3 Analysts have issued an Sonnet BioTherapeutics Holdings Inc EBITDA forecast 2025. The average Sonnet BioTherapeutics Holdings Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $-11.8m | 37.13% |
---|---|---|
2025 |
$-46.2m
292.57%
Unlock
|
2024 | -58,850.00% | 371.55% |
---|---|---|
2025 |
-4,530.00%
92.30%
Unlock
|
3 Sonnet BioTherapeutics Holdings Inc Analysts have issued a net profit forecast 2025. The average Sonnet BioTherapeutics Holdings Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
2024 | $-7.4m | 60.49% |
---|---|---|
2025 |
$-11.0m
47.98%
Unlock
|
2024 | -37,200.00% | 196.34% |
---|---|---|
2025 |
-1,079.52%
97.10%
Unlock
|
Sep '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -11.35 | -3.53 |
92.18% | 68.90% | |
P/E | negative | |
EV/Sales | 10.15 |
3 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast for earnings per share. The average Sonnet BioTherapeutics Holdings Inc EPS is
This results in the following potential growth metrics and future valuations:
2024 | $-11.35 | 92.18% |
---|---|---|
2025 |
$-3.53
68.90%
Unlock
|
Current | -1.16 | 113.39% |
---|---|---|
2025 |
-1.11
4.29%
Unlock
|
Based on analysts' sales estimates for 2025, the Sonnet BioTherapeutics Holdings Inc stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
Current | 10.35 | 218.69% |
---|---|---|
2025 |
10.15
1.96%
Unlock
|
Current | 12.41 | 57.47% |
---|---|---|
2025 |
12.17
1.96%
Unlock
|
Sonnet BioTherapeutics Holdings Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Chardan Capital |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 23 2024 |
Analyst Rating | Date |
---|---|
Locked
Chardan Capital:
Locked
➜
Locked
|
Apr 07 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 28 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Dec 20 2024 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 23 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.